Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,725 active trials51 approved drugs619 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,608 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04721015 | Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors | active not recruiting | Phase 1 | 81 | AbbVieINDUSTRY | 8 | Jul 3, 2025 | clinicaltrials |
| NCT04676477 | HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 246 | Daiichi SankyoINDUSTRY | 4 |
| Jun 22, 2025 |
| clinicaltrials |
| NCT05180799 | A Phase 1/2 Study of BA3071 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 320 | BioAtla, Inc.INDUSTRY | 2 | Jun 15, 2025 | clinicaltrials |
| NCT03970746 | Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC | active not recruiting | Phase 1 / Phase 2 | 73 | PDC*line Pharma SASINDUSTRY | 5 | May 29, 2025 | clinicaltrials |
| NCT05704985 | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | active not recruiting | Phase 1 | 39 | DEKA BiosciencesINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT04043195 | Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC(NSCLC) | active not recruiting | Phase 1 / Phase 2 | 30 | Hatim HusainOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT05441956 | TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 1 | 198 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT05919537 | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | active not recruiting | Phase 1 | 68 | Hummingbird BioscienceINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
| NCT04585035 | Study to Evaluate D-1553 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 180 | InventisBio Co., LtdINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT04165330 | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 56 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT06794957 | A Study of AL8326 in Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 158 | Advenchen Laboratories, LLCINDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT03546361 | CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT04440735 | A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Kahr MedicalINDUSTRY | 1 | Jan 9, 2025 | clinicaltrials |
| NCT05688280 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS(INJECTABL-1) | active not recruiting | Phase 1 / Phase 2 | 42 | Immunophotonics, Inc.INDUSTRY | 5 | Jan 8, 2025 | clinicaltrials |
| NCT05128487 | A Study of NDI 1150-101 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 106 | Nimbus Saturn, Inc.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | active not recruiting | Phase 1 / Phase 2 | 141 | 23andMe, Inc.INDUSTRY | 2 | Nov 15, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06542731 | An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 42 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jul 3, 2025source: clinicaltrials